 | • レポートコード：MRC2-11QY03770 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は心血管薬のグローバル市場について調査・分析したレポートです。種類別（レニン-アンジオテンシン系遮断薬、ベータ遮断薬、利尿薬、抗凝固薬、抗高脂血症薬）市場規模、用途別（高血圧、高脂血症）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別心血管薬の競争状況、市場シェア ・世界の心血管薬市場：種類別市場規模 2015年-2020年（レニン-アンジオテンシン系遮断薬、ベータ遮断薬、利尿薬、抗凝固薬、抗高脂血症薬） ・世界の心血管薬市場：種類別市場規模予測 2021年-2026年（レニン-アンジオテンシン系遮断薬、ベータ遮断薬、利尿薬、抗凝固薬、抗高脂血症薬） ・世界の心血管薬市場：用途別市場規模 2015年-2020年（高血圧、高脂血症） ・世界の心血管薬市場：用途別市場規模予測 2021年-2026年（高血圧、高脂血症） ・北米の心血管薬市場分析：米国、カナダ ・ヨーロッパの心血管薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの心血管薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の心血管薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの心血管薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Amgen、AstraZeneca、Bayer、Bristol Myers Squibb and Pfizer、Daiichi Sankyo、Johnson & Johnson、Merck & Co.、Novartis、Pfizer、Portola、Sanofi ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Cardiovascular Drugs and Therapy is a bimonthly peer-reviewed medical journal covering pharmacotherapy as it relates to cardiology. It was established in 1987 and is published by Springer Science+Business Media on behalf of the International Society of Cardiovascular Pharmacotherapy, of which it is the official journal. The editors-in-chief are Willem J. Remme (Carol Davila University of Medicine and Pharmacy) and Robert S. Rosenson (Icahn School of Medicine at Mount Sinai).
Geographically, North America captured lion’s share of global cardiovascular drugs market in 2016. However increasing adoption of generics in the U.S. is key concern area among key players. Asia Pacific market is projected to gain market share during the forecast period and is likely to be key revenue generator in the coming years. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals and incentives for generic production in countries such as Brazil, South Africa, Saudi Arabia, etc. is likely to boost market growth in Latin America and Middle East & Africa.
Market Analysis and Insights: Global Cardiovascular Drugs Market
The global Cardiovascular Drugs market size is projected to reach US$ 6066.5 million by 2026, from US$ 6014.9 million in 2020, at a CAGR of 0.8%% during 2021-2026.
Global Cardiovascular Drugs Scope and Market Size
Cardiovascular Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cardiovascular Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Cardiovascular Drugs market is segmented into
Renin-Angiotensin System Blockers
Beta Blockers
Diuretics
Anti-Clotting Agents
Antihyperlipidemic
Segment by Application, the Cardiovascular Drugs market is segmented into
Hypertension
Hyperlipidemia
Regional and Country-level Analysis
The Cardiovascular Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Cardiovascular Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Cardiovascular Drugs Market Share Analysis
Cardiovascular Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Cardiovascular Drugs business, the date to enter into the Cardiovascular Drugs market, Cardiovascular Drugs product introduction, recent developments, etc.
The major vendors covered:
Amgen
AstraZeneca
Bayer
Bristol Myers Squibb and Pfizer
Daiichi Sankyo
Johnson & Johnson
Merck & Co.
Novartis
Pfizer
Portola
Sanofi
1 Study Coverage
1.1 Cardiovascular Drugs Product Introduction
1.2 Market Segments
1.3 Key Cardiovascular Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Cardiovascular Drugs Market Size Growth Rate by Type
1.4.2 Renin-Angiotensin System Blockers
1.4.3 Beta Blockers
1.4.4 Diuretics
1.4.5 Anti-Clotting Agents
1.4.6 Antihyperlipidemic
1.5 Market by Application
1.5.1 Global Cardiovascular Drugs Market Size Growth Rate by Application
1.5.2 Hypertension
1.5.3 Hyperlipidemia
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Cardiovascular Drugs Market Size, Estimates and Forecasts
2.1.1 Global Cardiovascular Drugs Revenue 2015-2026
2.1.2 Global Cardiovascular Drugs Sales 2015-2026
2.2 Global Cardiovascular Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Cardiovascular Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Cardiovascular Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Cardiovascular Drugs Competitor Landscape by Players
3.1 Cardiovascular Drugs Sales by Manufacturers
3.1.1 Cardiovascular Drugs Sales by Manufacturers (2015-2020)
3.1.2 Cardiovascular Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Cardiovascular Drugs Revenue by Manufacturers
3.2.1 Cardiovascular Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Cardiovascular Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Cardiovascular Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Cardiovascular Drugs Revenue in 2019
3.2.5 Global Cardiovascular Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Cardiovascular Drugs Price by Manufacturers
3.4 Cardiovascular Drugs Manufacturing Base Distribution, Product Types
3.4.1 Cardiovascular Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Cardiovascular Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Cardiovascular Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Cardiovascular Drugs Market Size by Type (2015-2020)
4.1.1 Global Cardiovascular Drugs Sales by Type (2015-2020)
4.1.2 Global Cardiovascular Drugs Revenue by Type (2015-2020)
4.1.3 Cardiovascular Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Cardiovascular Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Cardiovascular Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Cardiovascular Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Cardiovascular Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Cardiovascular Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Cardiovascular Drugs Market Size by Application (2015-2020)
5.1.1 Global Cardiovascular Drugs Sales by Application (2015-2020)
5.1.2 Global Cardiovascular Drugs Revenue by Application (2015-2020)
5.1.3 Cardiovascular Drugs Price by Application (2015-2020)
5.2 Cardiovascular Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Cardiovascular Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Cardiovascular Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Cardiovascular Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Cardiovascular Drugs by Country
6.1.1 North America Cardiovascular Drugs Sales by Country
6.1.2 North America Cardiovascular Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Cardiovascular Drugs Market Facts & Figures by Type
6.3 North America Cardiovascular Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Cardiovascular Drugs by Country
7.1.1 Europe Cardiovascular Drugs Sales by Country
7.1.2 Europe Cardiovascular Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Cardiovascular Drugs Market Facts & Figures by Type
7.3 Europe Cardiovascular Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Cardiovascular Drugs by Region
8.1.1 Asia Pacific Cardiovascular Drugs Sales by Region
8.1.2 Asia Pacific Cardiovascular Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Cardiovascular Drugs Market Facts & Figures by Type
8.3 Asia Pacific Cardiovascular Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Cardiovascular Drugs by Country
9.1.1 Latin America Cardiovascular Drugs Sales by Country
9.1.2 Latin America Cardiovascular Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Cardiovascular Drugs Market Facts & Figures by Type
9.3 Central & South America Cardiovascular Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Cardiovascular Drugs by Country
10.1.1 Middle East and Africa Cardiovascular Drugs Sales by Country
10.1.2 Middle East and Africa Cardiovascular Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Cardiovascular Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Cardiovascular Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Amgen
11.1.1 Amgen Corporation Information
11.1.2 Amgen Description and Business Overview
11.1.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Amgen Cardiovascular Drugs Products Offered
11.1.5 Amgen Related Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Corporation Information
11.2.2 AstraZeneca Description and Business Overview
11.2.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.2.4 AstraZeneca Cardiovascular Drugs Products Offered
11.2.5 AstraZeneca Related Developments
11.3 Bayer
11.3.1 Bayer Corporation Information
11.3.2 Bayer Description and Business Overview
11.3.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Bayer Cardiovascular Drugs Products Offered
11.3.5 Bayer Related Developments
11.4 Bristol Myers Squibb and Pfizer
11.4.1 Bristol Myers Squibb and Pfizer Corporation Information
11.4.2 Bristol Myers Squibb and Pfizer Description and Business Overview
11.4.3 Bristol Myers Squibb and Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Bristol Myers Squibb and Pfizer Cardiovascular Drugs Products Offered
11.4.5 Bristol Myers Squibb and Pfizer Related Developments
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Corporation Information
11.5.2 Daiichi Sankyo Description and Business Overview
11.5.3 Daiichi Sankyo Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Daiichi Sankyo Cardiovascular Drugs Products Offered
11.5.5 Daiichi Sankyo Related Developments
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Corporation Information
11.6.2 Johnson & Johnson Description and Business Overview
11.6.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Johnson & Johnson Cardiovascular Drugs Products Offered
11.6.5 Johnson & Johnson Related Developments
11.7 Merck & Co.
11.7.1 Merck & Co. Corporation Information
11.7.2 Merck & Co. Description and Business Overview
11.7.3 Merck & Co. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Merck & Co. Cardiovascular Drugs Products Offered
11.7.5 Merck & Co. Related Developments
11.8 Novartis
11.8.1 Novartis Corporation Information
11.8.2 Novartis Description and Business Overview
11.8.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Novartis Cardiovascular Drugs Products Offered
11.8.5 Novartis Related Developments
11.9 Pfizer
11.9.1 Pfizer Corporation Information
11.9.2 Pfizer Description and Business Overview
11.9.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Pfizer Cardiovascular Drugs Products Offered
11.9.5 Pfizer Related Developments
11.10 Portola
11.10.1 Portola Corporation Information
11.10.2 Portola Description and Business Overview
11.10.3 Portola Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Portola Cardiovascular Drugs Products Offered
11.10.5 Portola Related Developments
11.1 Amgen
11.1.1 Amgen Corporation Information
11.1.2 Amgen Description and Business Overview
11.1.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Amgen Cardiovascular Drugs Products Offered
11.1.5 Amgen Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Cardiovascular Drugs Market Estimates and Projections by Region
12.1.1 Global Cardiovascular Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Cardiovascular Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Cardiovascular Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Cardiovascular Drugs Sales Forecast (2021-2026)
12.2.2 North America: Cardiovascular Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Cardiovascular Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Cardiovascular Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Cardiovascular Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Cardiovascular Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Cardiovascular Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Cardiovascular Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Cardiovascular Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Cardiovascular Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Cardiovascular Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Cardiovascular Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Cardiovascular Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Cardiovascular Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Cardiovascular Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Cardiovascular Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Cardiovascular Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Cardiovascular Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Cardiovascular Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Cardiovascular Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Cardiovascular Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Cardiovascular Drugs Market Segments
Table 2. Ranking of Global Top Cardiovascular Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Cardiovascular Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Renin-Angiotensin System Blockers
Table 5. Major Manufacturers of Beta Blockers
Table 6. Major Manufacturers of Diuretics
Table 7. Major Manufacturers of Anti-Clotting Agents
Table 8. Major Manufacturers of Antihyperlipidemic
Table 9. Global Cardiovascular Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 10. Global Cardiovascular Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 11. Global Cardiovascular Drugs Sales by Regions 2015-2020 (K Units)
Table 12. Global Cardiovascular Drugs Sales Market Share by Regions (2015-2020)
Table 13. Global Cardiovascular Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Cardiovascular Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 15. Global Cardiovascular Drugs Sales Share by Manufacturers (2015-2020)
Table 16. Global Cardiovascular Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Cardiovascular Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cardiovascular Drugs as of 2019)
Table 18. Cardiovascular Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Cardiovascular Drugs Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Cardiovascular Drugs Price (2015-2020) (USD/Unit)
Table 21. Cardiovascular Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Cardiovascular Drugs Product Type
Table 23. Date of International Manufacturers Enter into Cardiovascular Drugs Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Cardiovascular Drugs Sales by Type (2015-2020) (K Units)
Table 26. Global Cardiovascular Drugs Sales Share by Type (2015-2020)
Table 27. Global Cardiovascular Drugs Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Cardiovascular Drugs Revenue Share by Type (2015-2020)
Table 29. Cardiovascular Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 30. Global Cardiovascular Drugs Sales by Application (2015-2020) (K Units)
Table 31. Global Cardiovascular Drugs Sales Share by Application (2015-2020)
Table 32. North America Cardiovascular Drugs Sales by Country (2015-2020) (K Units)
Table 33. North America Cardiovascular Drugs Sales Market Share by Country (2015-2020)
Table 34. North America Cardiovascular Drugs Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Cardiovascular Drugs Revenue Market Share by Country (2015-2020)
Table 36. North America Cardiovascular Drugs Sales by Type (2015-2020) (K Units)
Table 37. North America Cardiovascular Drugs Sales Market Share by Type (2015-2020)
Table 38. North America Cardiovascular Drugs Sales by Application (2015-2020) (K Units)
Table 39. North America Cardiovascular Drugs Sales Market Share by Application (2015-2020)
Table 40. Europe Cardiovascular Drugs Sales by Country (2015-2020) (K Units)
Table 41. Europe Cardiovascular Drugs Sales Market Share by Country (2015-2020)
Table 42. Europe Cardiovascular Drugs Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Cardiovascular Drugs Revenue Market Share by Country (2015-2020)
Table 44. Europe Cardiovascular Drugs Sales by Type (2015-2020) (K Units)
Table 45. Europe Cardiovascular Drugs Sales Market Share by Type (2015-2020)
Table 46. Europe Cardiovascular Drugs Sales by Application (2015-2020) (K Units)
Table 47. Europe Cardiovascular Drugs Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Cardiovascular Drugs Sales by Region (2015-2020) (K Units)
Table 49. Asia Pacific Cardiovascular Drugs Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Cardiovascular Drugs Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Cardiovascular Drugs Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Cardiovascular Drugs Sales by Type (2015-2020) (K Units)
Table 53. Asia Pacific Cardiovascular Drugs Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Cardiovascular Drugs Sales by Application (2015-2020) (K Units)
Table 55. Asia Pacific Cardiovascular Drugs Sales Market Share by Application (2015-2020)
Table 56. Latin America Cardiovascular Drugs Sales by Country (2015-2020) (K Units)
Table 57. Latin America Cardiovascular Drugs Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Cardiovascular Drugs Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Cardiovascular Drugs Revenue Market Share by Country (2015-2020)
Table 60. Latin America Cardiovascular Drugs Sales by Type (2015-2020) (K Units)
Table 61. Latin America Cardiovascular Drugs Sales Market Share by Type (2015-2020)
Table 62. Latin America Cardiovascular Drugs Sales by Application (2015-2020) (K Units)
Table 63. Latin America Cardiovascular Drugs Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Cardiovascular Drugs Sales by Country (2015-2020) (K Units)
Table 65. Middle East and Africa Cardiovascular Drugs Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Cardiovascular Drugs Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Cardiovascular Drugs Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Cardiovascular Drugs Sales by Type (2015-2020) (K Units)
Table 69. Middle East and Africa Cardiovascular Drugs Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Cardiovascular Drugs Sales by Application (2015-2020) (K Units)
Table 71. Middle East and Africa Cardiovascular Drugs Sales Market Share by Application (2015-2020)
Table 72. Amgen Corporation Information
Table 73. Amgen Description and Major Businesses
Table 74. Amgen Cardiovascular Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 75. Amgen Product
Table 76. Amgen Recent Development
Table 77. AstraZeneca Corporation Information
Table 78. AstraZeneca Description and Major Businesses
Table 79. AstraZeneca Cardiovascular Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 80. AstraZeneca Product
Table 81. AstraZeneca Recent Development
Table 82. Bayer Corporation Information
Table 83. Bayer Description and Major Businesses
Table 84. Bayer Cardiovascular Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 85. Bayer Product
Table 86. Bayer Recent Development
Table 87. Bristol Myers Squibb and Pfizer Corporation Information
Table 88. Bristol Myers Squibb and Pfizer Description and Major Businesses
Table 89. Bristol Myers Squibb and Pfizer Cardiovascular Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 90. Bristol Myers Squibb and Pfizer Product
Table 91. Bristol Myers Squibb and Pfizer Recent Development
Table 92. Daiichi Sankyo Corporation Information
Table 93. Daiichi Sankyo Description and Major Businesses
Table 94. Daiichi Sankyo Cardiovascular Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 95. Daiichi Sankyo Product
Table 96. Daiichi Sankyo Recent Development
Table 97. Johnson & Johnson Corporation Information
Table 98. Johnson & Johnson Description and Major Businesses
Table 99. Johnson & Johnson Cardiovascular Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 100. Johnson & Johnson Product
Table 101. Johnson & Johnson Recent Development
Table 102. Merck & Co. Corporation Information
Table 103. Merck & Co. Description and Major Businesses
Table 104. Merck & Co. Cardiovascular Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 105. Merck & Co. Product
Table 106. Merck & Co. Recent Development
Table 107. Novartis Corporation Information
Table 108. Novartis Description and Major Businesses
Table 109. Novartis Cardiovascular Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 110. Novartis Product
Table 111. Novartis Recent Development
Table 112. Pfizer Corporation Information
Table 113. Pfizer Description and Major Businesses
Table 114. Pfizer Cardiovascular Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 115. Pfizer Product
Table 116. Pfizer Recent Development
Table 117. Portola Corporation Information
Table 118. Portola Description and Major Businesses
Table 119. Portola Cardiovascular Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 120. Portola Product
Table 121. Portola Recent Development
Table 122. Sanofi Corporation Information
Table 123. Sanofi Description and Major Businesses
Table 124. Sanofi Cardiovascular Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 125. Sanofi Product
Table 126. Sanofi Recent Development
Table 127. Global Cardiovascular Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 128. Global Cardiovascular Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 129. Global Cardiovascular Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 130. Global Cardiovascular Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 131. North America: Cardiovascular Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 132. North America: Cardiovascular Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 133. Europe: Cardiovascular Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 134. Europe: Cardiovascular Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 135. Asia Pacific: Cardiovascular Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 136. Asia Pacific: Cardiovascular Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 137. Latin America: Cardiovascular Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 138. Latin America: Cardiovascular Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 139. Middle East and Africa: Cardiovascular Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 140. Middle East and Africa: Cardiovascular Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 141. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 142. Key Challenges
Table 143. Market Risks
Table 144. Main Points Interviewed from Key Cardiovascular Drugs Players
Table 145. Cardiovascular Drugs Customers List
Table 146. Cardiovascular Drugs Distributors List
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
List of Figures
Figure 1. Cardiovascular Drugs Product Picture
Figure 2. Global Cardiovascular Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Renin-Angiotensin System Blockers Product Picture
Figure 4. Beta Blockers Product Picture
Figure 5. Diuretics Product Picture
Figure 6. Anti-Clotting Agents Product Picture
Figure 7. Antihyperlipidemic Product Picture
Figure 8. Global Cardiovascular Drugs Sales Market Share by Application in 2020 & 2026
Figure 9. Hypertension
Figure 10. Hyperlipidemia
Figure 11. Cardiovascular Drugs Report Years Considered
Figure 12. Global Cardiovascular Drugs Market Size 2015-2026 (US$ Million)
Figure 13. Global Cardiovascular Drugs Sales 2015-2026 (K Units)
Figure 14. Global Cardiovascular Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Cardiovascular Drugs Sales Market Share by Region (2015-2020)
Figure 16. Global Cardiovascular Drugs Sales Market Share by Region in 2019
Figure 17. Global Cardiovascular Drugs Revenue Market Share by Region (2015-2020)
Figure 18. Global Cardiovascular Drugs Revenue Market Share by Region in 2019
Figure 19. Global Cardiovascular Drugs Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Cardiovascular Drugs Revenue in 2019
Figure 21. Cardiovascular Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Cardiovascular Drugs Sales Market Share by Type (2015-2020)
Figure 23. Global Cardiovascular Drugs Sales Market Share by Type in 2019
Figure 24. Global Cardiovascular Drugs Revenue Market Share by Type (2015-2020)
Figure 25. Global Cardiovascular Drugs Revenue Market Share by Type in 2019
Figure 26. Global Cardiovascular Drugs Market Share by Price Range (2015-2020)
Figure 27. Global Cardiovascular Drugs Sales Market Share by Application (2015-2020)
Figure 28. Global Cardiovascular Drugs Sales Market Share by Application in 2019
Figure 29. Global Cardiovascular Drugs Revenue Market Share by Application (2015-2020)
Figure 30. Global Cardiovascular Drugs Revenue Market Share by Application in 2019
Figure 31. North America Cardiovascular Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 32. North America Cardiovascular Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Cardiovascular Drugs Sales Market Share by Country in 2019
Figure 34. North America Cardiovascular Drugs Revenue Market Share by Country in 2019
Figure 35. U.S. Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 36. U.S. Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 38. Canada Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Cardiovascular Drugs Market Share by Type in 2019
Figure 40. North America Cardiovascular Drugs Market Share by Application in 2019
Figure 41. Europe Cardiovascular Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 42. Europe Cardiovascular Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Cardiovascular Drugs Sales Market Share by Country in 2019
Figure 44. Europe Cardiovascular Drugs Revenue Market Share by Country in 2019
Figure 45. Germany Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 46. Germany Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 48. France Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 50. U.K. Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 52. Italy Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 54. Russia Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Cardiovascular Drugs Market Share by Type in 2019
Figure 56. Europe Cardiovascular Drugs Market Share by Application in 2019
Figure 57. Asia Pacific Cardiovascular Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 58. Asia Pacific Cardiovascular Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Cardiovascular Drugs Sales Market Share by Region in 2019
Figure 60. Asia Pacific Cardiovascular Drugs Revenue Market Share by Region in 2019
Figure 61. China Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 62. China Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 64. Japan Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 66. South Korea Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 68. India Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 70. Australia Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 72. Taiwan Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 74. Indonesia Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 76. Thailand Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 78. Malaysia Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 80. Philippines Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 82. Vietnam Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Cardiovascular Drugs Market Share by Type in 2019
Figure 84. Asia Pacific Cardiovascular Drugs Market Share by Application in 2019
Figure 85. Latin America Cardiovascular Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 86. Latin America Cardiovascular Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Cardiovascular Drugs Sales Market Share by Country in 2019
Figure 88. Latin America Cardiovascular Drugs Revenue Market Share by Country in 2019
Figure 89. Mexico Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 90. Mexico Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 92. Brazil Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 94. Argentina Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Cardiovascular Drugs Market Share by Type in 2019
Figure 96. Latin America Cardiovascular Drugs Market Share by Application in 2019
Figure 97. Middle East and Africa Cardiovascular Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 98. Middle East and Africa Cardiovascular Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Cardiovascular Drugs Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Cardiovascular Drugs Revenue Market Share by Country in 2019
Figure 101. Turkey Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 102. Turkey Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 104. Saudi Arabia Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Cardiovascular Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 106. U.A.E Cardiovascular Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Cardiovascular Drugs Market Share by Type in 2019
Figure 108. Middle East and Africa Cardiovascular Drugs Market Share by Application in 2019
Figure 109. North America Cardiovascular Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 110. North America Cardiovascular Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Cardiovascular Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 112. Europe Cardiovascular Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Cardiovascular Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 114. Asia Pacific Cardiovascular Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Cardiovascular Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 116. Latin America Cardiovascular Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Cardiovascular Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 118. Middle East and Africa Cardiovascular Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed
高血圧治療薬の世界市場（～2026年） The standard definition of high blood pressure is determined by the Joint National Committee (JNC) on Detection, Evaluation, and Diagnosis of High Blood Pressure. A person is considered to have high blood pressure after three to six elevated blood pressure measurements over several months. These def…- 心血管疾患治療薬の世界市場（～2026年） Market Analysis and Insights: Global Cardiovascular Disease Drugs Market The global Cardiovascular Disease Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Cardiovascular Disease Drugs Scope and Market Size Cardio…
- 抗高血圧薬の世界市場（～2026年） Market Analysis and Insights: Global Anti-Hypertensive Drugs Market The global Anti-Hypertensive Drugs market size is projected to reach US$ 40970 million by 2026, from US$ 40270 million in 2020, at a CAGR of 1.6%% during 2021-2026. Global Anti-Hypertensive Drugs Scope and Market Size Anti-Hypertens…
- 心血管情報システム（CVIS）の世界市場（～2026年） CVIS is a data driven technology i.e. information of patient comes from integrated hemodynamic system, echo machines, electrocardiogram (ECG) carts along with third-party integrated monitoring systems all these are stored with the remaining measurements and nurse charting captured in the course of t…
- 心血管インプラントの世界市場（～2026年） Cardiac disease is a condition that involves narrowing or blockage of blood vessels. Cardiac disease is caused due to heart rhythm problems, smoking, high cholesterol, and high blood pressure. Coronary artery disease, myocardial infarction, peripheral arterial disease, atherosclerosis, and heart fai…